Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Homo sapiens | tumor protein p53 | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Homo sapiens | lamin A/C | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.0648 | 0.1871 |
Echinococcus granulosus | cadherin EGF LAG seven pass G type receptor | 0.0019 | 0.0085 | 0.0085 |
Brugia malayi | Latrophilin receptor protein 2 | 0.0019 | 0.0085 | 0.0126 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0033 | 0.0429 | 0.1312 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.1122 | 0.3426 |
Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0017 | 0.0044 | 0.0135 |
Echinococcus multilocularis | cadherin EGF LAG seven pass G type receptor | 0.0019 | 0.0085 | 0.0085 |
Echinococcus granulosus | lamin dm0 | 0.0033 | 0.0429 | 0.0429 |
Loa Loa (eye worm) | intermediate filament protein | 0.0033 | 0.0429 | 0.1312 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0033 | 0.0429 | 0.1193 |
Brugia malayi | calcium-independent alpha-latrotoxin receptor 2, putative | 0.0019 | 0.0085 | 0.0126 |
Schistosoma mansoni | lamin | 0.0033 | 0.0429 | 0.3323 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.0648 | 0.5434 |
Loa Loa (eye worm) | latrophilin receptor protein 2 | 0.0019 | 0.0085 | 0.0259 |
Brugia malayi | intermediate filament protein | 0.0033 | 0.0429 | 0.1193 |
Brugia malayi | MH2 domain containing protein | 0.0144 | 0.3274 | 1 |
Echinococcus granulosus | GPCR family 2 | 0.0019 | 0.0085 | 0.0085 |
Echinococcus multilocularis | musashi | 0.0033 | 0.0429 | 0.0429 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0144 | 0.3274 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.1134 | 0.3374 |
Echinococcus granulosus | diuretic hormone 44 receptor GPRdih2 | 0.0019 | 0.0085 | 0.0085 |
Schistosoma mansoni | lamin | 0.0033 | 0.0429 | 0.3323 |
Echinococcus granulosus | lamin | 0.0033 | 0.0429 | 0.0429 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.1134 | 0.3463 |
Schistosoma mansoni | intermediate filament proteins | 0.0033 | 0.0429 | 0.3323 |
Echinococcus granulosus | intermediate filament protein | 0.0033 | 0.0429 | 0.0429 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.0648 | 0.198 |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.0414 | 0.1265 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0144 | 0.3274 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 0.0429 | 0.1312 |
Onchocerca volvulus | 0.006 | 0.1122 | 1 | |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.1134 | 0.3463 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.1134 | 0.3374 |
Loa Loa (eye worm) | hypothetical protein | 0.0019 | 0.0085 | 0.0259 |
Schistosoma mansoni | cellular tumor antigen P53 | 0.006 | 0.1122 | 1 |
Echinococcus multilocularis | GPCR, family 2 | 0.0019 | 0.0085 | 0.0085 |
Echinococcus multilocularis | lamin dm0 | 0.0033 | 0.0429 | 0.0429 |
Echinococcus multilocularis | lamin | 0.0033 | 0.0429 | 0.0429 |
Echinococcus multilocularis | diuretic hormone 44 receptor GPRdih2 | 0.0019 | 0.0085 | 0.0085 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 2.8184 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 3.9811 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 11.2202 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 14.1254 um | PUBCHEM_BIOASSAY: qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 25.1189 um | PUBCHEM_BIOASSAY: qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent). (Class of assay: confirmatory) [Related pubchem assays: 2158 (Confirmation qHTS Assay for Inhibitors of Cruzain), 2249 (Probe Development Summary of Promiscuous Inhibitors (Artifacts) of Cruzain), 2161 (qHTS Assay for Inhibitors of Papain: Counterscreen for Cruzain Assay), 1478 (qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent))] | ChEMBL. | No reference |
Potency (binding) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PubChem BioAssay. qHTS Assay to Find Inhibitors of Pin1. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.